Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2011-08
Cisplatin ototoxicity affecting cochlear implant benefit.
ABSTRACT
OBJECTIVE
Report a case of loss of cochlear implant benefit after cisplatin therapy to treat osteosarcoma. Examine the implications for the loci of cisplatin-associated cochleotoxicity.
STUDY DESIGN
Retrospective case review.
SETTING
Tertiary referral center.
PATIENTS
Single case study.
INTERVENTION(S)
None.
MAIN OUTCOME MEASURE(S)
Cochlear implant programming levels.
RESULTS
Increase in cochlear implant programming T- and C-levels after cisplatin therapy.
CONCLUSION
Cisplatin therapy likely affects spiral ganglion cells. It seems that auditory cells other than outer hair cells in the organ of Corti are affected by cisplatin because the hearing sensitivity of this patient with nonfunctioning outer hair cells declined after receiving chemotherapy. Implications of these findings are discussed.
Related Questions
New answer by at Vanderbilt University School of Medicine (January 2, 2026)
Cisplatin is commonly used for radiosensitization in patients being treated for gynecologic cancer. Ototoxicity is a common side effect of cisplatin. It is caused by the death...